Extensive thromboembolic event as initial presentation of monoclonal gammopathy of undertermined significance

Thrombosis and Haemostasis

Volumn 96, Issue 1, 2006, Pages 93-94

  Righini, Marc ^a   Boehlen, Françoise ^a   Gueddi, Salah ^a   Le Gal, Grégoire ^b   de Moerloose, Philippe ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMORAL VEIN; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; ILIAC VEIN; IMMUNOELECTROPHORESIS; INFERIOR CAVA VEIN; LEG EDEMA; LEG THROMBOSIS; LIMB PAIN; LOW BACK PAIN; LUNG EMBOLISM; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; NORMOCHROMIC NORMOCYTIC ANEMIA; POPLITEAL VEIN; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; THORAX PAIN; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; HUMANS; MALE; MONOCLONAL GAMMOPATHIES, BENIGN; PAIN; PARAPROTEINS; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33746668655     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-02-0123     Document Type: Article

References (12)

1. Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the "well" elderly. Am J Med 1987; 82: 39-45.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-9.
3. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-9.
4. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
5. Srkalovic G, Elson P, Trebisky B, et al. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002; 19: 219-26.
6. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
7. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.
8. Minnema MC, Fijnheer R, De Groot PG, et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445-9.
9. Sallah S, Husain A, Wan J, et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15: 1490-4.
10. Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101: 558-66.
11. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165: 1782-7.
12. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-7.